OncoPlex Diagnostics’ Androgen Receptor Protein Addition Breast Cancer Proteomic Panel Offers Potential Diagnostic Benefit To Patients

OncoPlex Diagnostics’ Androgen Receptor Protein Addition Breast Cancer Proteomic Panel Offers Potential Diagnostic Benefit To Patients
Androgen ReceptorMaryland-based OncoPlex Diagnostics, a CAP-accredited, CLIA-certified laboratory that offers a novel solution for solubilizing tumor cell proteins taken from FFPE tissue and offering samples with absolute quantitation measures of unique peptides, recently announced that it has expanded its Breast Cancer Proteomic Panel by developing and adding a quantitative androgen receptor (AR) assay. With the addition of the AR, OncoPlex claims that their Diagnostics Breast Panel can now simultaneously measure several clinically relevant tumor proteins through the use of mass spectrometry in order to provide oncologists with the data they need to make the best therapy selection decisions. The newly expanded Breast Cancer Proteomic Panel was recently presented at the 13th Annual International Future of Breast Cancer Meeting, which was held in Huntington Beach, CA on July 19. Dr. April Speed, a Breast Surgical Oncologist from Atlanta, Georgia, specifically noted the inclusion of AR as an effective biomarker as part of the company's multi-protein quantitation panel, along with HER2, HER3, EGFR, MET, IGF1R, ROS1, and PD-L1. In addition to these biomarkers, the Panel also includes the chemotherapy guidance markers hENT1, FR-alpha, RRM1, TOPO1, SPARC, and TOPO2A. These biomarkers, according to OncoPlex, can be include
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.